Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis

Therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids

Kimiaki Utsugisawa, Yuriko Nagane, Shigeaki Suzuki, Norihiro Suzuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The advent of effective immune treatment has meant that myasthenia gravis (MG) is most often not lethal. However, many MG patients still find it difficult to maintain daily activities due to chronic residual fatigability and long-term side effects of medication, since full remission without immune treatment is not common. Our analysis demonstrated that disease severity, dose of oral corticosteroids, and depressive state are the major independent factors negatively associated with self-reported QOL (MG-QOL15-J score). It is noteworthy that oral corticosteroid, the first-line agent for MG, is negatively associated with patients' QOL. When the analysis took into account MGFA postintervention status and dose of oral prednisolne (PSL), the MG-QOL15-J score of MM status patients taking ≤5 mg PSL per day is identically low (i.e., just as good QOL) as that seen in CSR and is a target of treatment. In order to veer away from high-dose oral corticosteroids and to achieve early MM or better status with PSL ≤5 mg/day, we advocate the early aggressive treatment strategy that can achieve early improvement by performing an aggressive therapy using combined treatment with plasmapheresis and high-dose intravenous methylprednisolone and then maintain an improved clinical status using low-dose oral corticosteroids and calcineurin inhibitors (cyclosporine microemulsion and tacrolimus). The early stages of MG are susceptible to treatment with calcineurin inhibitors. When using cyclosporine microemulsion for MG, blood concentrations 2 h after administration (C2) correlate with clinical improvement and immediately before administration (C0) with side effects (increased serum creatinine and/or hypertension). Monitoring of C2 and C0 levels is useful to estimate efficacy and safety of the drug.

Original languageEnglish
Pages (from-to)1047-1050
Number of pages4
JournalClinical Neurology
Volume52
Issue number11
DOIs
Publication statusPublished - 2012

Fingerprint

Myasthenia Gravis
Adrenal Cortex Hormones
Therapeutics
Cyclosporine
Plasmapheresis
Methylprednisolone
Tacrolimus
Direction compound
Calcineurin Inhibitors
Creatinine
Hypertension
Safety
Serum
Pharmaceutical Preparations

Keywords

  • Calcineurin inhibitors
  • Corticosteroids
  • Health-related quality of life
  • Myasthenia gravis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

@article{bcc4a9e8b3804a55a5fabb91ac1a7c4c,
title = "Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: Therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids",
abstract = "The advent of effective immune treatment has meant that myasthenia gravis (MG) is most often not lethal. However, many MG patients still find it difficult to maintain daily activities due to chronic residual fatigability and long-term side effects of medication, since full remission without immune treatment is not common. Our analysis demonstrated that disease severity, dose of oral corticosteroids, and depressive state are the major independent factors negatively associated with self-reported QOL (MG-QOL15-J score). It is noteworthy that oral corticosteroid, the first-line agent for MG, is negatively associated with patients' QOL. When the analysis took into account MGFA postintervention status and dose of oral prednisolne (PSL), the MG-QOL15-J score of MM status patients taking ≤5 mg PSL per day is identically low (i.e., just as good QOL) as that seen in CSR and is a target of treatment. In order to veer away from high-dose oral corticosteroids and to achieve early MM or better status with PSL ≤5 mg/day, we advocate the early aggressive treatment strategy that can achieve early improvement by performing an aggressive therapy using combined treatment with plasmapheresis and high-dose intravenous methylprednisolone and then maintain an improved clinical status using low-dose oral corticosteroids and calcineurin inhibitors (cyclosporine microemulsion and tacrolimus). The early stages of MG are susceptible to treatment with calcineurin inhibitors. When using cyclosporine microemulsion for MG, blood concentrations 2 h after administration (C2) correlate with clinical improvement and immediately before administration (C0) with side effects (increased serum creatinine and/or hypertension). Monitoring of C2 and C0 levels is useful to estimate efficacy and safety of the drug.",
keywords = "Calcineurin inhibitors, Corticosteroids, Health-related quality of life, Myasthenia gravis",
author = "Kimiaki Utsugisawa and Yuriko Nagane and Shigeaki Suzuki and Norihiro Suzuki",
year = "2012",
doi = "10.5692/clinicalneurol.52.1047",
language = "English",
volume = "52",
pages = "1047--1050",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis

T2 - Therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids

AU - Utsugisawa, Kimiaki

AU - Nagane, Yuriko

AU - Suzuki, Shigeaki

AU - Suzuki, Norihiro

PY - 2012

Y1 - 2012

N2 - The advent of effective immune treatment has meant that myasthenia gravis (MG) is most often not lethal. However, many MG patients still find it difficult to maintain daily activities due to chronic residual fatigability and long-term side effects of medication, since full remission without immune treatment is not common. Our analysis demonstrated that disease severity, dose of oral corticosteroids, and depressive state are the major independent factors negatively associated with self-reported QOL (MG-QOL15-J score). It is noteworthy that oral corticosteroid, the first-line agent for MG, is negatively associated with patients' QOL. When the analysis took into account MGFA postintervention status and dose of oral prednisolne (PSL), the MG-QOL15-J score of MM status patients taking ≤5 mg PSL per day is identically low (i.e., just as good QOL) as that seen in CSR and is a target of treatment. In order to veer away from high-dose oral corticosteroids and to achieve early MM or better status with PSL ≤5 mg/day, we advocate the early aggressive treatment strategy that can achieve early improvement by performing an aggressive therapy using combined treatment with plasmapheresis and high-dose intravenous methylprednisolone and then maintain an improved clinical status using low-dose oral corticosteroids and calcineurin inhibitors (cyclosporine microemulsion and tacrolimus). The early stages of MG are susceptible to treatment with calcineurin inhibitors. When using cyclosporine microemulsion for MG, blood concentrations 2 h after administration (C2) correlate with clinical improvement and immediately before administration (C0) with side effects (increased serum creatinine and/or hypertension). Monitoring of C2 and C0 levels is useful to estimate efficacy and safety of the drug.

AB - The advent of effective immune treatment has meant that myasthenia gravis (MG) is most often not lethal. However, many MG patients still find it difficult to maintain daily activities due to chronic residual fatigability and long-term side effects of medication, since full remission without immune treatment is not common. Our analysis demonstrated that disease severity, dose of oral corticosteroids, and depressive state are the major independent factors negatively associated with self-reported QOL (MG-QOL15-J score). It is noteworthy that oral corticosteroid, the first-line agent for MG, is negatively associated with patients' QOL. When the analysis took into account MGFA postintervention status and dose of oral prednisolne (PSL), the MG-QOL15-J score of MM status patients taking ≤5 mg PSL per day is identically low (i.e., just as good QOL) as that seen in CSR and is a target of treatment. In order to veer away from high-dose oral corticosteroids and to achieve early MM or better status with PSL ≤5 mg/day, we advocate the early aggressive treatment strategy that can achieve early improvement by performing an aggressive therapy using combined treatment with plasmapheresis and high-dose intravenous methylprednisolone and then maintain an improved clinical status using low-dose oral corticosteroids and calcineurin inhibitors (cyclosporine microemulsion and tacrolimus). The early stages of MG are susceptible to treatment with calcineurin inhibitors. When using cyclosporine microemulsion for MG, blood concentrations 2 h after administration (C2) correlate with clinical improvement and immediately before administration (C0) with side effects (increased serum creatinine and/or hypertension). Monitoring of C2 and C0 levels is useful to estimate efficacy and safety of the drug.

KW - Calcineurin inhibitors

KW - Corticosteroids

KW - Health-related quality of life

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=84880516953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880516953&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.52.1047

DO - 10.5692/clinicalneurol.52.1047

M3 - Article

VL - 52

SP - 1047

EP - 1050

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -